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Abstract
Background: The objective of this review is to determine the effectiveness of Harpagophytum
procumbens preparations in the treatment of various forms of musculoskeletal pain.
Methods: Several databases and other sources were searched to identify randomized controlled
trials, quasi-randomized controlled trials, and controlled clinical trials testing Harpagophytum
preparations in adults suffering from pain due to osteoarthritis or low back pain.
Results: Given the clinical heterogeneity and insufficient data for statistical pooling, trials were
described in a narrative way, taking into consideration methodological quality scores. Twelve trials
were included with six investigating osteoarthritis (two were identical trials), four low back pain,
and three mixed-pain conditions.
Conclusions: There is limited evidence for an ethanolic Harpagophytum extract containing less
than <30 mg harpagoside per day in the treatment of knee and hip osteoarthritis. There is
moderate evidence of effectiveness for (1) the use of a Harpagophytum  powder at 60 mg
harpagoside in the treatment of osteoarthritis of the spine, hip and knee; (2) the use of an aqueous
Harpagophytum  extract at a daily dose of 100 mg harpagoside in the treatment of acute
exacerbations of chronic non-specific low back pain; and (3) the use of an aqueous extract of
Harpagophytum procumbens at 60 mg harpagoside being non-inferior to 12.5 mg rofecoxib per day
for chronic non-specific low-back pain (NSLBP) in the short term. Strong evidence exists for the
use of an aqueous Harpagophytum extract at a daily dose equivalent of 50 mg harpagoside in the
treatment of acute exacerbations of chronic NSLBP.
Background
Natives in the steppes of South and Southwest Africa use
the secondary root tubers of Harpagophytum procumbens
(H) for the treatment of various diseases, including musc-
uloskeletal complaints. For more than half a century, var-
ious preparations from H have been continuously used in
Europe and have become an established traditional treat-
ment for rheumatic complaints. The monograph of the
European Scientific Cooperative on Phytotherapy
(ESCOP) [1] recommends H preparations for painful
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osteoarthritis and relief of low back pain in a dosage
equivalent of up to nine grams of crude plant material and
over a treatment period of at least two to three months. It
has been suggested that the plant material should contain
not less than 1.2% of the constituent harpagoside, an iri-
doid glycoside. Pharmacological studies indicate that in
various animal models (e.g. the writhing test in mice) [2]
the extract is more effective than its marker compound
harpagoside. However, a number of contradictory find-
ings make it difficult to draw definitive conclusions on the
analgesic and anti-inflammatory effect of H preparations
[3].
Recent in-vitro studies indicate that preparations from H
may interact with the inflammatory cascade, including the
cytokines [4-6]. Moreover, a significant decrease in stimu-
lated production of matrix-degrading enzymes has
recently been shown in isolated chondrocytes [7] and a
dose-dependent weak elastase inhibition [8].
The objective of this review was to determine the effective-
ness of Harpagophytum preparations in the treatment of
musculoskeletal pain.
Methods
Searching
Two reviewers (JG) and (SC) conducted electronic
searches using the following databases: PUBMED (1966
up to September 16, 2003), EMBASE (OVID technologies:
1980 to wk 40 2003), Cochrane Controlled Trials Regis-
try, Cochrane Musculoskeletal specialized register, Disser-
tation Abstracts, BIDS ISI, and the Cochrane
Complementary Medicine Fields Specialized Register. The
search strategy was developed by combining a highly sen-
sitive method for isolating controlled clinical trials devel-
oped for the Cochrane Collaboration [9] [see appendix 1]
with a variety of indexing and text words specific to the
intervention (H. procumbens) and musculoskeletal condi-
tions. Search strategies were modified for each database
[for PUBMED strategy see appendix 2]. One reviewer (SC)
contacted experts and acquired relevant citations. In addi-
tion, manufacturers of commercial Harpagophytum prepa-
rations and content experts were contacted and asked to
contribute published and unpublished material. Refer-
ence lists in review articles and the retrieved trials were
searched for further trials.
Study selection
Trials that met the criteria outlined in Table 1 were
included. Two individuals (JG & SC) independently
reviewed titles and abstracts to determine study inclusion.
A consensus method was used to resolve disagreements
about inclusion of studies.
Data abstraction
Two reviewers (SC, JG) extracted data from each trial
using a standardized form. The following data were
extracted from each study: authors' names; date of publi-
cation; country of origin; type of study, including number
of study centers; participants (numbers, disease(s), char-
acteristics of the study population (age, size, weight, gen-
der)); duration of acute exacerbation or chronic disease;
baseline values with details on pain and previous treat-
ments; additional treatments; types of outcome measures;
summary statistics; timing of outcome assessment; with-
drawals and drop-outs; and adverse events. Blinding to
authors, institution or journal title was not done, given
the contradictory evidence relating blinded reviewing and
bias [10]; additionally, two reviewers (JG and SC) were
very familiar with the literature.
Methodological quality assessment
Methodological quality was assessed using the criteria list
developed by van Tulder et al (1997; 2003) [10,11]. Spe-
cifically, the internal validity criteria A, B, C, E, F, G, H, I,
J, K, L1, N, and O were used. Each criterion could be
scored as yes (Y), no (N), or don't know (DK). The score
of Y reflects the fulfillment of that criterion. The scoring of
N reflects lack of fulfillment of that criterion. The scoring
of DK reflects the inability to determine whether or not
the criterion was fulfilled.
High quality studies are defined as those that fulfill more
than 50% (>6) of the quality criteria. Sensitivity analyses
were carried out to explore the results when the definition
of high quality trials was set at 40 % (>5) and 60% (>7)
fulfillment of the quality criteria.
According to the Van Tulder Scoring [10,11], the levels of
evidence were defined as follows:
1. Strong – consistent findings among multiple high qual-
ity RCTs
2.  Moderate  – consistent findings among multiple low
quality RCTs and/or CCTs and/or one high quality RCT
3. Limited – one low quality RCT and/or CCT
4. Conflicting – inconsistent findings among multiple tri-
als (RCTs and/or CCTs)
5. No evidence from trials – no RCTs or CCTs
Planned subgroup analyses included: (1) pain site, (2)
type of pain (acute (≤ 6 weeks duration), sub-acute (6 to
12 weeks duration), and chronic pain (> 12 weeks)), and
(3) comparison (botanical medicine (considering prepa-BMC Complementary and Alternative Medicine 2004, 4:13 http://www.biomedcentral.com/1472-6882/4/13
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ration form) versus placebo and botanical medicine ver-
sus other treatment).
Results
A total of 130 citations were isolated from electronic
searches and all abstracts were retrieved. A total of three
additional references were supplied by content experts. A
total of 120 papers were excluded because of publication
type (reviews or reports) or because of improper trial
design. The complete references were retrieved for the
remaining 13 trials. All 13 references were included in the
current review [12-24]. Of these, two trials were duplicate
publications [13,21], leaving 12 trials with unique data.
A total of five randomized trials included 385 patients
(range 46 to 122) with osteoarthritis of the hip or the knee
[12,13,18,21-23]. Three of these trials were placebo con-
trolled [12,18,22], and two were compared to standard
pharmaceutical treatment forms [13,23]. The H prepara-
tions in these trials included a powder of crude plant
material [13,22], a 60% ethanolic extract (solvent 60%
ethanol)[12,18], and an aqueous extract [23].
A total of four trials included 505 patients (range 88 to
197) with acute exacerbation's of chronic non-specific
low back pain [14-17]. All were randomized controlled
trials, with two using placebo control [14,16], one using
various conventional treatment controls (e.g. NSAIDs,
exercise, massage, nerve blocks, acupuncture, etc.) [15],
and one using a Cox-2 inhibitor control (Vioxx) [17].
These trials all used aqueous extracts of H.
The last three trials included 215 patients with various
forms of musculoskeletal pain (range 50 to 100)
[19,20,24]. Schmelz et al (1997)[24] included subjects
with acute exacerbations of joint arthrosis, chronic low
back pain, and rheumatic muscle pain. Guyader (1984)
[20] included subjects with gonarthrosis, poly-arthrosis,
coxarthrosis, and arthrosis of the cervical spine, lumbar
spine, or the nerve root canal. Gobel et al (2001) [19]
included subjects with pain and/or muscle tension in
shoulder, neck, and/or back. All three trials were placebo
controlled. Schmelz et al (1997) [24] used an aqueous
extract, Guyader (1984) [20] dried mother tincture (sol-
vent 45% ethanol), and Gobel et al (2001) [19] an eth-
anolic extract (solvent 60% ethanol).
All trials, except for two [12,24], reported adverse events
for the interventions.
Methodological quality and sensitivity analysis
Ratings for each trial on each quality criterion are reported
in Table 2. Of the trials including patients with various
forms of arthritis, four were considered high quality
[13,18,22,23] and one low quality [12] with 60% and
50% cutoffs for methodological quality fulfillment; all tri-
als were considered high quality if the cutoff was 40%
[12,13,18,22,23]. There were very few instances of inade-
quate reporting (DK scores) in these trials (5/52) criteria
assessed across trials); in cases where inadequate report-
ing was found, these tended not to be the same criteria
across trials. The authors of these trials were not contacted
for clarification regarding these items.
Of the trials utilizing subjects with acute exacerbations of
chronic non-specific low back pain, all four were
considered to be of high methodological quality regard-
less of the cutoff [14-17]. Methodological aspects that
were unclear in the published reports were clarified by the
study author (SC).
Of those trials including a mixed sample of subjects
[19,20,24], two were low quality when the cutoff was
60%, or 50% and all three were high quality when the cut-
off was 40%. All trials did not adequately report sufficient
information to judge baseline similarity, if co-interven-
tions were avoided or comparable, or if there were any
adverse events [24].
Harpagophytum preparations for osteoarthritis
Powdered crude plant material compared to placebo
Lecomte & Costa (1992) [22] utilized a powder of the sec-
ondary roots of H in 89 subjects (44 placebo; 45 H) with
98 locations of arthrosis (with two locations in three sub-
jects in the placebo group and six in the H group). Of
those with one location, 31 had osteoarthritis of the
spine, 18 of the cervical spine, 14 of the hip, and 30 of the
knee. Results favoured the H group. Detailed descriptions
of each original study included in this review are provided
in Table 3.
Powdered crude plant material compared to diacerhein
Chantre et al (2000) [13] gave H cryodried drug powder
(proprietary product HarpadolR) or Diacerhein (D), to
122 subjects with acute exacerbations of hip and knee.
Groups did not differ significantly in sponanteous pain or
the Lequesne index, though differences from baseline
were larger for the H group. Subjects in the H group used
less diclofenac (mean = 21 tablets) than those in the D
group (60 tablets) and also used less acetominophen-caf-
feine (H = 40 tablets and D = 60 tablets).
H extract (solvent 60% ethanol) compared to placebo
Biller (2002) [12] gave knee arthrosis participants a H
product named FlexilogesR or placebo in addition to ibu-
profen (at 800 mg ibuprofen during weeks 1–8, 400 mg
during weeks 9 – 16), and only H or placebo during weeks
17–20. The main outcome measure was the responder
rate, which allowed a WOMAC pain score increase of upBMC Complementary and Alternative Medicine 2004, 4:13 http://www.biomedcentral.com/1472-6882/4/13
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to 20% and no additional consumption of ibuprofen in
weeks 17 to 20. Results favoured the H group.
Frerick et al (2001) [18] gave 46 individuals with acute
exacerbations of coxarthrosis FlexilogesR or placebo in
addition to ibuprofen (at 800 mg ibuprofen during weeks
1–8, 400 mg during weeks 9–16) and only H or placebo
during weeks 17–20. The main outcome was the
responder rate, which was defined as the number of
patients that required fewer than 4000 mg ibuprofen and
had a pain score increase of no more than 20% on the
WOMAC component pain during weeks 17 to 20. Results
indicated more responders in the H group.
Table 1: Inclusion criteria for considering studies for this review
Types of studies Randomized controlled trials (RTCs), quasi-randomized controlled trials, and controlled clinical trials (CCTs) with 
no language restriction.
Types of participants Adults suffering from pain in the musculoskeletal system due to osteoarthritis or low back pain.
Types of interventions Studies utilizing preparations of Harpagophytum procumbens were included. Preparations may differ in the solvent 
(water, alcohol) used to prepare the extract (if not crude powdered plant material is used), the drug extract ratio, 
and the galenic aplication form. They also differ in the content of the active principles (the sum of active ingredients) 
and in the quantity of the co-active marker compound harpagoside (Chrubasik et al. 1996, Sporer and Chrubasik 
1999).
Types of outcome measures Primary outcome: pain (e.g. visual analogue scale, visual rating scale, pain component of the disease-specific Arhus 
Low Back Pain Index, component pain of the Western Ontario MacMaster (WOMAC) instrument). Secondary 
outcomes: number of pain-free patients (defined as being pain-free on at least five days in the last treatment week 
without taking any rescue medication see above), functional indices (e.g. Lequesne index, finger-ground distance), 
and generic outcome measures [global assessments, health assessment questionnaire (HAQ)] or the consumption of 
additional analgesic treatment.
Table 2: Methodological quality of controlled trials of Harpagophytum procumbens
Methodological Quality 
Criteria
Gobel 
et al, 
2001
Schmel
z et al, 
1999
Guyader
, 1984
Chrubasik 
et al, 1996
Chrubasik 
et al, 1997
Chrubasik 
et al, 1999
Chrubasik 
et al, 2003
Chantre 
et al, 
2000
Frerick 
et al, 
2001
Lecomte 
& Costa, 
1992
Biller 
et al, 
2002
Schruffer, 
1980
A Were eligibility criteria 
specified?
nn n y y y y y y n y n
B Was randomization 
appropriate?
yy y y y y y y y y y y
C Was treatment allocation 
concealed?
yy y y n y y y y y y y
E Were groups similar at 
baseline regarding 
important prognostic 
indicators?
dk dk n y y y y y n dk dk dk
F Were outcome 
measure(s) and the control 
interventions explicitly 
described?
yy y y y y y y y y y y
G Were co-interventions 
avoided or comparable?
dk dk dk y y y y y y dk y y
H Were the outcome 
measures relevant?
yy y y y y y y n y n y
I Were adverse events 
described?
yd k y y y y y y y y n y
J Were drop-outs 
described?
ny y y y y y y n d k n y
K Was the sample size 
based on a priori power 
calculation?
n n ny n y nynn n n
L1 Did the study include 
intention-to-treat analysis? 
and/or
ny n n y y y y n y n y
N Were point estimates 
and measures of variability 
presented for the POM?
yn n y y y y y y y n n
O Was the timing of 
outcomes appropriate?
yy n y y y y y y y y Y
Total 7 7 6 12 11 13 12 13 8 8 6 9BMC Complementary and Alternative Medicine 2004, 4:13 http://www.biomedcentral.com/1472-6882/4/13
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Aqueous extract compared to NSAID
Schruffler (1980) [23] compared H (proprietary product,
SalusR,) with phenylbutazone among 40 individuals with
acute exacerbations of rheumatic joint and muscle pain
and 10 with gouty arthritis. Results favoured the H group.
Harpagophytum procumbens for acute exacerbation of chronic 
non-specific low back pain (NSLBP)
Aqueous extract compared to placebo
In the Chrubasik study (1996) [14], 128 patients suffering
from pseudo-radiating or non-radiating NSLBP were allo-
cated to receive either a proprietary extract, DoloteffinR,,
or placebo. Results favoured the H group (see Table 4). Of
the 59 patients in the H group, five dropped out, one of
these due to tachycardia. Of the 59 patients in the P group,
four dropped out for unknown reasons. A total of four
adverse effects occurred in the H group. These consisted of
two individuals with nausea/emesis due to the tramadol,
one patient with repeated tussive irritation, and the
patient with tachycardia mentioned above. A total of 10
adverse events occurred in the P group. These included
nausea (N = 2), and one patient each of nausea/vertigo
Table 3: Description of trials included in this review
Study Sample
Size
Condition;
mean age
(range)
Harpagophytum
Intervention / control
Outcome measures and effects Adverse effects Reviewer's Overall
Conclusions
Schrüffler 1980 
(Germany)
50 Osteoarthritis;
51 years
2500 mg/ day, (harpagoside less
than 30 mg per day) /
Phenylbutazone for 4 weeks
mean pain improvements: H 80%,
Phenylbutazone 72%; physical
impairment: H n = 1, Phenybutazone
n = 5; morning stiffness: H n = 2,
Phenybutazone n = 5
0 H vs 4
Phenylbutazone
H better than
Phenylbutazone
Lecomte and 
Costa 1992 
(France)
89 Osteoarthritis;
(55–75) years
2000 mg/day (Harpagoside
content estimated indirectly as
60 mg per day) / placebo for 60
days
mean pain improvement: H 38%, P
25% p < .05; finger-ground distance
modified Schober test (cm) mean
improvement: H 16%, P 6% p < .05
none for either group H better than placebo
Biller 2002 
(Germany)
78 Osteoarthritis;
not stated
4500 mg/day, (harpagoside
content estimated at < 30 mg
per day) / placebo for 20 weeks
responders: H 90%, P 80% p-value
not stated; mean consumption of
ibuprofen: H .1, P .5 tablets
not stated H better than placebo
Chantre et al. 
2000 (France)
122 Osteoarthritis;
62 years
4500 mg / day, (57 mg
harpagoside per day) /
Diacerhein for 16 weeks
difference after 16 weeks between
groups as measured by Lequesne
functional index: less than 10 mm NS
(intention-to-treat analysis with not
all possible confounders considered)
10 H vs 21 Diacerhein H not worse than
diacerhein
Frerick et al. 
2001 (Germany)
46 Osteoarthritis;
59 years
4500 mg/day, (< 30 mg
harpagoside per day) / placebo
for 20 weeks
responders: H 71%, P 41% p=.041;
WOMAC component pain NS (type
of statistical analysis not stated)
8 H vs 7 P H better than placebo
Chrubasik et al. 
1996b 
(Germany)
118 Back pain; 54
years
4500 mg/day, (50 mg
harpagoside per day) / placebo
for 4 weeks
mean tramadol consumption: H 99 ±
157 mg, P 102 ± 250 mg p =.44;
number of pain-free patients at 4th
week: H 9 P 1 p=.008; percentage
change Arhus component pain: H
34%, P 6% p=.016 (per protocol
analysis)
4 H vs 10 P not on primary
outcome measure
Chrubasik et al. 
1997 (Germany)
102 Back pain; 49
years
4500 mg/day, (30 mg
harpagoside per day) /
conventionally treating
physicians administering oral
NSAIDs, physical exercises, or
paravertaebral injections for 6
weeks
number of pain-free patients 4th
week: H 16, C12 NS; number of pain
free patients 6th week: H 20, C 23
NS; percentage change Arhus
component pain after four weeks: H
23%, C 22% p=.95; after 6 weeks H
33%, C 38% p=.38
5 H vs 0 C H not worse than C
Chrubasik et al. 
1999 (Germany)
197 Back pain; 56
years
4500 and 9000 mg/day, (50 and
100 mg harpagoside per day) /
placebo for 4 weeks
number of pain-free patients: H-100
18%, H-50 9%, P 5% p=.027);
percentage change Arhus
component pain: H-100 vs H-50 vs P
NS (intention-to-treat analysis)
10 P, 18 H-50, 17 H-
100
H better than placebo
Chrubasik et al. 
2003a 
(Germany)
88 Back pain; 62
years
4500 mg/day, (60 mg
harpagoside per day) /
Rofecoxib for 6 weeks
number of pain-free patients: H 22%,
Rofecoxib 11% NS; percentage
change Arhus component pain: H
30%, Rofecoxib 29% (intention-to-
treat analysis)
14 H, 14 Rofecoxib H not worse than
Rofecoxib
Schmelz and 
Hämmerle 1999 
(Germany)
100 Mixed pain; not
stated
4500 mg/day, (30 mg
harpagoside per day) / placebo
for 30 days
free of low back pain: H n = 4, P n =
2; free of other pain: H n = 5, P n = 0
(confounders not considered)
not stated H better than placebo
Guyader 1984 
(France)
50 Mixed pain; 64
years
Harpagoside content estimated
indirectly as <20 mg
harpagoside per day / placebo
for 1–3 'cycles' of 21 days each
mean pain improvements: H 72%, P
65% (confounders not considered)
6 H vs 3 P H better than placebo
Goebel et al. 
2001 (Germany)
65 Mixed pain; 28
years
4500 mg/day, (< 30 mg
harpagoside per day) / placebo
for 28 days
4 H vs 2 P H better than placebo
Key: NS = not significant; H = harpagophytum; P = placebo; WOMAC = Western Ontario and McMaster Universities Arthritis IndexBMC Complementary and Alternative Medicine 2004, 4:13 http://www.biomedcentral.com/1472-6882/4/13
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due to tramadol, fatigue/vertigo, vertigo alone, diuresis/
normalization of constipation (i.e. intractable constipa-
tion), constipation (several times), diuresis (several
times), and sleep disturbances (permanent).
An additional study by Chrubasik et al (1999) [16] rand-
omized subjects suffering from pseudo-radiating or non-
radiating NSLBP were allocated to receive the proprietary
extract WS1531, at a dose equivalent to either 4500 mg H
(with 50 mg harpagoside per day, H50) or 9000 mg H /day
(with 100 mg harpagoside per day, H100), or placebo (P;
N = 66). Participants had acute exacerbations of non-spe-
cific low back pain; current pain that was > 5 on a VAS (0–
10). The median durations of chronic pain were P 15
years, H50 15 years, H100 15 years. The number of patients
with acute exacerbations of greater than 3 months for each
group was P 54 (82%), H50 53 (82%), H100 55 (83%).
Current pain and Arhus scores were similar among all
groups. The principle outcome measure, the number of
patients who were pain-free without the permitted rescue
medication for 5 days out of the last treatment week was
3 (P), 6 (H50) and 10 (H100) (p = 0.027, one-tailed
Cochrane-Armitage test). The authors found significant
improvements in pain in both H groups as compared with
the placebo group. A subgroup analysis found differences
between groups for those without pain radiating to the
legs (H100 40%, H50 43% and P 23%; P = 0.017) and for
those without a neurological deficit (H100 40%, H50 60%
and P 20%; P = 0.034).
Aqueous extract compared to NSAID
Chrubasik et al (2003) [17] randomized 88 individuals
suffering from pseudo-radiating or non-radiating NSLBP
recieved either the proprietary extract DoloteffinR (N = 44)
or VioxxR (rofecoxib; R; N = 44). The percentage of sub-
jects with chronic pain of > 6 days for each group was H
84%, R 84% and acute pain of > 90 days in H 91%, R 89%.
Results indicated statistically non-significant difference
between H and R. Also, a total of 21 (group H) and 13
(group R) patients used tramadol, with the average con-
sumption being 230 mg (H) and 133 mg (R). A total of
seven drop-outs occurred due to adverse events (H = 1; R
= 6); two others resulted from excessive low back pain (R
= 2). There were a total of seven protocol violations. A
total of 14 participants in each group had adverse events
with gastrointenstinal complaints, equaling eight in the H
group and nine in the R group, with more severe events in
the R group. Two adverse events were reported to be unre-
lated to the study medication in the H group.
Aqueous extract compared to various conventional treatments
In another study by Chrubasik et al (1997) [15], partici-
pants suffering from non-radiating NSLBP were rand-
omized to receive either the proprietary extract JurcubaR or
conventional treatments (NSAIDs, exercise, massage,
nerve blocks, acupuncture). Subjects' pain was > 5 (VAS
0–10) on at least two of the following five scores: pain at
rest, while sitting, lying, and walking or at night. The
median duration of acute pain was six weeks for both
groups. The median duration of chronic pain was 120
months for the H group and 72 months for the control
group. There were no statistically significant differences
between the groups.
Harpagophytum preparations for mixed pain conditions
Dried mother tincture compared to placebo
In a placebo controlled double-blind study, Guyader
(1984) [20] included 50 patients with poly-arthrosis (N =
14), coxarthrosis (N = 2), arthrosis of the cervical spine (N
= 11), lumbar spine (N = 2), and arthrosis of the nerve
root canal (N = 6). Subjects were given either "Extract G",
a dried mother tincture of Devil's claw (H), or placebo (P)
for one to three cycles (18 single P, 16 single H, 6 PH, 4
HP, 2 HH, 1 PPP, 1 PHH, 1 PPH, 1 PHP) of 21 days with
seven day intervals. Outcome measures included pain at
rest, pain during exercise, joint pressure pain, pain while
walking (in cases of cox- and gonarthrosis), and pain at
night. All outcomes were taken 10 days after each cycle
and assessed on a five-point rating scale for amount of
pain (no pain = 0, mild = 1, moderate = 2, severe = 3,
excrutiating = 4). A total of 70 cycles were analyzed (37
cycles for P and 33 for H) and a mean pain improvement
of 72% in the H group and 65% in the placebo group (p
< 0.05) was found. Drop-outs included two subjects. Dur-
ing the H cycles, six adverse events occurred, including
nausea, gastralgia, diarrhea, severe constipation, pruritic
eruptions with erythema, and generalized pruritis. During
the P cycles, five adverse events were observed, including
gastralgia, sweating, headache, and aerophagy.
Aqueous extract compared to placebo
In a double-blind, placebo-controlled trial, Schmelz et al
(1997) [24] randomized 100 individuals with acute exac-
erbations of joint arthrosis (N = 29 (H), N = 27 (P)),
chronic low back pain (N = 14 H, N = 17 P), and rheu-
matic muscle pain (N = 7 H, N = 6 P). Subjects were given
either the proprietary extract ArthrotabsR  containing
extract based on 4500 mg crude plant material (equiva-
lent of 30 mg harpagoside) per day or a placebo for 30
days. Outcome measures included a subjective pain scale
(no pain, mild pain, moderate pain, severe pain, excruti-
ating pain) at baseline and after four weeks of treatment.
The number of pain-free individuals with low back pain
was H n = 4, P n = 2, and for other pain sites H n = 5, P n
= 0.
Harpagophytum extract (solvent 60% ethanol) compared to 
placebo
Gobel et al (2001) [19] conducted a double-blind study in
65 individuals with pain or muscle tenseness in shoulder,BMC Complementary and Alternative Medicine 2004, 4:13 http://www.biomedcentral.com/1472-6882/4/13
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neck, and/or back having lasted for 14 days prior to the
study. They were randomized to placebo (N = 32) or a
proprietary extract (Rivoltan; N = 31). The daily extract
dosage was based on 4500 mg crude plant material
(equivalent to <30 mg harpagoside per day). Outcomes
included a visual analogue scale for pain (0–50 mm) as
well as an experimental test battery for pain and muscle
tension before and after treatment. In the per-protocol
analysis the Hgroup had less pain than the P group. A total
of two individuals dropped out of the trial with four
adverse events occurring in the H group versus two in the
P group.
Discussion
Osteoarthritis of the knee, hip, and spine as well as non-
specific low back pain may be associated with pain, stiff-
ness, limitation of function, and diminished quality of life
[25]. Although treatment guidelines recommend simple
analgesics as first-line drugs [26], surveys indicate that
NSAIDs are used in preference to simple analgesics
despite the lower safety-margin and the higher cost
[11,27,28]. Because of the high incidence of NSAID-
related adverse events and complications in the gastroin-
testinal and cardiovascular systems (especially in the eld-
erly), and the high costs related to adverse events (i.e.
gastrointestinal bleeding or perforation), additional med-
ical attendances, diagnostic procedures, treatments and
admissions to hospital, alternatives to NSAID therapy
should be strongly considered [29-33].
This qualitative analysis of the 12 trials suggests that spe-
cific preparations and doses of Harpagophytum procumbens
may be effective in various types of musculoskeletal pain
conditions. Statistical pooling was not possible because of
a lack of adequate data and clinical heterogeneity. The
sensitivity analysis for methodological quality revealed
that the trials on low back pain were of high quality, the
trials on osteoarthritis were of high quality except one
moderate quality study, and the trials on mixed pain con-
ditions were of moderate quality. The quality of reporting
in most of these trials was good. In order to increase trans-
parency, trialists should refer to the CONSORT statement
in designing and reporting clinical trials of herbal medic-
inal products [34].
One high quality trial indicates that there is moderate evi-
dence of effectiveness for powdered H plant material at a
dose equivalent to 60 mg of harpagoside per day for oste-
oarthritis of the spine, hip, and knee. However, because of
the clinical heterogeneity of patients in this trial, a con-
firmatory study is required to firmly establish efficacy for
each location of osteoarthritis. In one high quality study,
4500 mg powder containing 57 mg harpagoside in the
daily dosage showed moderate evidence for non-inferior-
ity to diacerhein in patients suffering from acute exacerba-
tions of osteoarthritis in the hip and knee.
Two trials employed an ethanolic extract (solvent 60%
ethanol) containing less than 30 mg harpagoside per day
in patients with osteoarthritis of the knee [12] and hip
[18]. Both trials showed statisitically significant favoura-
ble results for the H group in terms of percentage of
responders. However, the definition of responder in these
trials may be questioned because of an allowance of pain
increase up to 20% and additional rescue medication in
one of the studies [18]. Therefore, given the low method-
ological quality of the trials and the lack of clinically sig-
nificant differences between groups, we conclude there is
limited evidence for the use of an ethanolic H extract
based on 4500 mg crude plant material per day in patients
with osteoarthritis of the knee and hip. Additional high
quality trials must be done to determine the efficacy of
Harpagophytum procumbens in osteoathritis. These trials
must include homogenous pain conditions and must test
H against standard osteoarthitis medications. Addition-
ally, trialists should consider using symptom severity
outcome measures that have proven validity and reliabil-
ity, such as visual analogue scales [35-37], osteoarthritis
specific outcome measures (e.g. WOMAC, Lequesne
Index) [35-38], and health-related quality of life instru-
ments (e.g. Medical Outcomes Survey Short-Form 36)
[35,37,38].
A total of four high quality trials tested various dosages of
Hextract in acute exacerbations of chronic non-specific
low back pain. Two trials with a total of 325 patients
showed that an aqueous extract at the equivalent daily
dosage of 50 mg harpagoside appears to reduce pain in
patients with acute episodes of chronic NSLBP greater
than does placebo [14,16]. Therefore, the 50 mg harpago-
side per dose of an aqueous extract of H can be said to
have strong evidence for the treatment of acute episodes
of chronic NSLBP in the short term. Additionally, a one
year survey indicates that the aqueous extract is well toler-
ated [38]. One trial with 197 patients showed that an
aqueous H extract at the equivalent daily dose of 100 mg
harpagoside appears to reduce pain in patients with acute
episodes of chronic NSLBP greater than does placebo [16].
Therefore, the 100 mg harpagoside per dose of an aque-
ous H extract has moderate evidence for the treatment of
acute episodes of chronic NSLBP in the short term. Supe-
riority of the higher dose was seen in the primary outcome
(number of pain-free patients) but not in the secondary
outcome measure. Therefore, there is moderate evidence
for superiority of the 100 mg H dose to the 50 mg H dose.
However, additional trials are required to confirm superi-
ority of 100 mg H over 50 mg H. It is possible that a sub-
group of individuals with neurological deficits (e.g.
radiation into the leg) may respond well to the 100 mgBMC Complementary and Alternative Medicine 2004, 4:13 http://www.biomedcentral.com/1472-6882/4/13
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harpagoside dose, yet more research is required to clarify
this.
An aqueous extract of H at the equivalent daily dose of 60
mg harpagoside appears to be equivalent to 12.5 mg
Rofecoxib in improving pain in individuals with acute
episodes of chronicNSLBP [17]. Therefore, a 60 mg daily
harpagoside dose in aqueous extract of H has moderate
evidence for being not inferior to 12.5 mg rofecoxib per
day in the treatment of acute episodes of chronic NSLBP
in the short term. Additional high quality trials, especially
over longer treatment periods, are mandatory. Further-
more, equivalence trials testing Harpagophytum procumbens
against standard treatments will clarify relative efficacy
and safety.
The final trials (two of moderate [19,24] and of poor qual-
ity [20] included heterogeneous musculoskeletal pain
conditions. Therefore, it is difficult to reach any
conclusions on the basis of these trials. Future trials
should attempt to include homogenous pain conditions.
The results obtained with the proprietary Harpagophytum
products containing aqueous extracts can neither be trans-
ferred to an aqueous extract containing less harpagoside
in the daily dosage [41] or to a product containing an eth-
anolic extract. This can only be done if the ethanolic
extract was shown to be essentially similar to aqueous
extract, and if both extracts have the same qualitative and
quantitative composition of co-active constituents, same
pharmaceutical form, and bioequivalence in terms of
safety and efficacy [40]. With 60% ethanol as solvent, only
half the amount of harpagoside (and possibly other co-
active constituents) is extracted compared to water as sol-
vent [42]; therefore, it is of great importance that a con-
firmatory study provide evidence of effectiveness for the
ethanolic extract.
Since the "active principle" has not yet been identified for
Harpagophytum procumbens, the constituent harpagoside is
used as a marker for standardization of Harpagophytum
preparations. For harpagoside, the dose-dependent
absorption into systemic circulation has been shown and
may be related to lipoxygenase inhibition [43]. However,
it remains to be established if the inhibitory effect on leu-
kotriene production corresponds to therapeutic efficacy.
Future research should attempt to identify the active con-
stituent or profile of constituents that relate to therapeutic
efficacy in order to make extract dosing transparent.
There are several drawbacks to the present study. First, this
is a qualitative review and as such it does not provide a
quantitative summary of results, thus making it difficult
to determine the size of effect of each intervention. Sec-
ondly, this review includes a small number of trials, often
with small sample sizes. This makes it difficult to state
definitive conclusions of efficacy and suggests the need for
more trials. On the other hand, the trials reviewed were
generally of good methodological quality and have sev-
eral statistically significant and clinically significant
effects. Therefore, these trials help us reach some clear
conclusions regarding the use of specific preparations and
doses of Harpagophytum procumbens for osteoarthritis and
non-specific low back pain. Another strength of this study
is the comprehensive search strategy, the methodological
quality assessment, and the use of an accepted method for
a best evidence synthesis. Future reviews may attempt to
statistically combine the results of such trials into a meta-
analysis.
Conclusions
There is limited evidence for an ethanolic Harpagophytum
extract containing less than <30 mg harpagoside per day
in the treatment of knee and hip osteoarthritis. There is
moderate evidence of effectiveness for (1) the use of a
Harpagophytum powder at 60 mg harpagoside in the treat-
ment of osteoarthritis of the spine, hip and knee; (2) the
use of an aqueous Harpagophytum extract at a daily dose of
100 mg harpagoside in the treatment of acute exacerba-
tions of chronic non-specific low back pain; and (3) the
use of an aqueous extract of Harpagophytum procumbens at
60 mg harpagoside being non-inferior to 12.5 mg
rofecoxib per day for chronic non-specific low back pain
(NSLBP) in the short term. Strong evidence exists for the
use of an aqueous Harpagophytum extract at a daily dose
equivalent of 50 mg harpagoside in the treatment of acute
exacerbations of chronic NSLBP.
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Appendix 1
Highly sensitive search strategy for randomized controlled
trial searches using PUBMED
(randomized controlled trial [pt] OR controlled clinical
trial [pt] OR randomized controlled trials [mh] OR ran-BMC Complementary and Alternative Medicine 2004, 4:13 http://www.biomedcentral.com/1472-6882/4/13
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dom allocation [mh] OR double-blind method [mh] OR
single-blind method [mh] OR clinical trial [pt] OR clinical
trials [mh] OR (clinical trial [tw]) OR ((singl* [tw] OR
doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask*
[tw] OR blind* {tw])) OR (latin square [tw]) OR placebos
[mh] OR placebo* [tw] OR random* [tw] OR research
design [mh:noexp] OR comparative study [mh] OR evalu-
ation studies [mh] OR follow-up studies [mh] OR pro-
spective studies [mh] OR cross-over studies [mh] OR
control* [tw] OR prospectiv* [tw] or volunteer* [tw])
NOT (animal [mh] NOT human [mh])
Appendix 2
PUBMED search strategy
(randomized controlled trial [pt] OR controlled clinical
trial [pt] OR randomized controlled trials [mh] OR ran-
dom allocation [mh] OR double-blind method [mh] OR
single-blind method [mh] OR clinical trial [pt] OR clinical
trials [mh] OR (clinical trial [tw]) OR ((singl* [tw] OR
doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask*
[tw] OR blind* {tw])) OR (latin square [tw]) OR placebos
[mh] OR placebo* [tw] OR random* [tw] OR research
design [mh:noexp] OR comparative study [mh] OR evalu-
ation studies [mh] OR follow-up studies [mh] OR pro-
spective studies [mh] OR cross-over studies [mh] OR
control* [tw] OR prospectiv* [tw] or volunteer* [tw])
NOT (animal [mh] NOT human [mh]) AND ("harpago-
phytum procumbens" OR (devil's AND claw)) AND (pain
OR "musculoskeletal pain" OR "muscle pain" OR "skele-
tal pain" OR "bone pain" OR "joint pain" OR "extremity
pain" OR myaligia OR osteoarthritis OR "rheumatoid
arthritis" OR arthrosis OR "low back pain" OR lumbago
OR "back pain") NOT review
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